Virtus ETF Advisers LLC Paratek Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$4.07 - $5.3 $82,942 - $108,008	-20,379 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.7 - $7.24 $5,019 - $7,732	-1,068 Reduced 4.98%	20,379 $99,000
Q2 2021 Aug 10, 2021	BUY	$6.81 - $10.93 $146,054 - $234,415	21,447 New	21,447 $146,000
Q4 2018 Feb 05, 2019	SELL	$4.8 - $11.6 $204,403 - $493,974	-42,584 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$9.05 - $10.95 $282,233 - $341,486	-31,186 Reduced 42.27%	42,584 $413,000
Q2 2018 Aug 10, 2018	BUY	$10.2 - $13.9 $316,577 - $431,414	31,037 Added 72.63%	73,770 $752,000
Q1 2018 May 14, 2018	BUY	$12.65 - $18.85 $292,885 - $436,434	23,153 Added 118.25%	42,733 $556,000
Q4 2017 Feb 14, 2018	BUY	$17.45 - $25.6 $84,702 - $124,262	4,854 Added 32.96%	19,580 $350,000
Q3 2017 Nov 14, 2017	BUY	$18.9 - $28.2 $25,458 - $37,985	1,347 Added 10.07%	14,726 $370,000
Q2 2017 Aug 14, 2017	BUY	N/A	13,379	13,379 $322,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.